| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 31 Jan 2025 | 23 Jan 2025 |
| Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024. Re Outcome of Board Meeting (As Per BSE Announcement Dated on 31/01/2025) | ||
| Board Meeting | 25 Oct 2024 | 17 Oct 2024 |
| Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve Intimation of Board Meeting - To consider the unaudited Financial Results for the Quarter and Half Year ended September 30 2024. Outcome of the Board Meeting held on October 25, 2024 - Approval of Unaudited Financial Results for quarter and half year ended September 30, 2024 Approval of Unaudted Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 25.10.2024) | ||
| Board Meeting | 19 Jul 2024 | 10 Jul 2024 |
| Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2024 inter alia to consider and approve Intimation of Board Meeting -July 19 2024 The Company has submitted to the Stock Exchange the Outcome of Board Meeting held on July 19, 2024 Unaudited Financial Results for June 30, 2024 (As per BSE Announcement Dated on 19/07/2024) | ||
| Board Meeting | 29 May 2024 | 22 May 2024 |
| Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Intimation of Board Meeting and recommendation of Final Dividend if any. Outcome of Board Meeting (As Per BSE Announcement Dated on: 29/05/2024) | ||
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
